⁦@jeffsparks⁩ knocking it out of the park presenting our findings on b/tsDMARD associations with COVID-19 outcomes ⁦@eular_org⁩ ⁦@EULAR_Press⁩ check out our full paper just published in ⁦@ARD_BMJ⁩ https://t.co/jcA1LN45R3

Dr Palomäki on influence of MUC5B promotor variant on ILD risk in RA and non-RA. Lifetime risk ILD 14.5% for RA+MUC5B+, 5.2% for RA+MUC5B-, 3.9% RA-MUC5B+ 1.3% RA-MUC5B- @RheumNow #EULAR2021 Abstr#OP0007 https://t.co/BnexQE1Pw9

Dr Ponte presenting on use of halo sign on TA US to monitor GCA disease activity. Seems good, present and increased in 16/17 (94.1%) cases of first disease relapse @RheumNow #EULAR2021 #AbstrOP0055 https://t.co/T6hKjkb4AT

Abs#OP0009 presents 8 min web-based video for COVID vax education sent via text message. 76% more likely to get vax. #EULAR2021. @RheumNow. Pts need to hear from their rheumatologists our thoughts on vax, ideally in person, but phone is great outreach https://t.co/aimGBufYpe

Excellent job by @jeffsparks @zach_wallace_md @rheum_covid on Abs#0P0006 at #EULAR2021. ⭐️RTX and JAKi: increased COVID severity, not seen in IL-6 or ABA. Critical findings, but confounding role of co-morbidities/ILD/cancer, esp in RTX patients? @RheumNow

Dr. Tani: Who has trouble tapering below 5mg/d prednisone in SLE ☑️Older patients ☑️High disease activity ☑️Skin and MSK manifestations ☑️Pts treated before 2000. Try to avoid long-term steroid usage early in the disease course, as it gets harder over time. #EULAR2021, @RheumNow

Excellent talk by @LCalabreseDO on the balance of the immune response! ⭐️Exhausted T cells seen in rheumatic dz, chronic infections, cancers, severe COVID-19 ⭐️CPI for treatment of latent infections? CPI for treatment of COVID? 🤔 Abs#OP7137 #EULAR2021 @RheumNow https://t.co/18rvFkpPTx

Secukinumab effective in AS patients, irrespective of gender AQUILA 52 week study ⭐️improvement in BASDAI, PGA, severity of depressive mood in both men and women ⭐️women had overall higher disease burden in global functioning and depressive mood POS0899 #EULAR2021 @RheumNow

Dr Atienza-Mateo presents abstract #POS0595 on abatacept in RA-ILD. Abatacept surprisingly appeared to be equally good in stabilising FVC and DLCO in both UIP and NSIP patterns in RA-ILD. @RheumNow #EULAR2021 Abstr#POS0595 https://t.co/kHUxWXnaBG

I'm presenting data on COVID-19 in Irish rheumatic disease patients. Age, number comorbidities, glucocorticoids, associated increased hospitalisation. Inflammatory arthritis associated decreased hospitalisation. @RheumNow #EULAR2021 #AbstrPOS1162 https://t.co/0gKxiMNYTf

#EULAR2021 recommendations: RMDs face no more risk of contracting COVID-19, no current evidence of worse prognosis. Do you tell patients similar stats? @RheumNow

#EULAR2021 recommendations on mgmt of RMD in COVID: continue treatment if symptom free, steroids at lowest dose. @Rheumnow. https://t.co/U5zr7EHvTv

Seeing the sites of Paris at virtual #eular2021. Follow on @RheumNow along with @RichardPAConway @MeralElRamahiMD @Yuz6Yusof @Stiddyo @KDAO2011 @uptoTate @AurelieRheumo @drdavidliew @Janetbirdope https://t.co/w18REG08nz

@RheumNow I will be tweeting alongside an amazing team @RichardPAConway @MeralElRamahiMD @Stiddyo @KDAO2011 @uptoTate @Yuz6Yusof @drdavidliew @ejdein1 @Janetbirdope @TammyTilley & last but not least Dr Cush! Follow them and @Rheumnow to stay tuned for the latest science! #EULAR2021

There seem to be quite a few #EULAR2021 abstracts that are identical (or nearly) to #ACR20 abstracts, eg mavrilimumab and GUSTO in vasculitis oral presentation section. Have the rules changed?